Generic Name: tazemetostat
Drug Class: Targeted Therapy Medications
Approval Status: Experimental
Generic Version Available: No
Tazverik is an EZH2 methyltransferase inhibitor approved for the treatment of inoperable epithelioid sarcoma (a type of soft tissue cancer) and for relapsed or refractory follicular lymphoma.
Tazverik is the first approved selective inhibitor of EZH2 methyltransferase. It works by preventing methylation of a specific histone, which alters gene expression patterns associated with cancer cell growth.
In a Phase II study of people with epithelioid sarcoma, Tazverik demonstrated a 15% response rate, with two thirds of responses lasting at least six months. In a study of people with follicular lymphoma, the overall response rate was 69%. Tazverik was first approved in January 2020.
Tazverik is taken as a pill twice daily with or without food.
The most common adverse events in clinical trials of Tazverik were pain, fatigue, nausea, decreased appetite, vomiting and constipation. The drug has been shown to raise he risk of developing other cancers including lymphoma and leukemia. It has known interactions with other medications processed by cytochrome P450 enzymes. Tazverik may cause fetal harm if used during pregnancy.
Last Reviewed: June 22, 2020